title: The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication.
abstract: OBJECTIVE
  To examine the association between HIV infection status and the receipt of lipid lowering therapy based on National Cholesterol Education Program/Adult Treatment Panel (NCEP/ATP III) guidelines and to assess whether HIV viral load and hepatitis C (HCV) status alters that association.
  
  
  METHODS
  A cross-sectional analysis of survey, laboratory, and pharmacy data from 1,577 male participants (59% HIV infected) of the Veterans Aging Cohort Five-Site Study, a prospective observational cohort of U.S. veterans with and without HIV infection.
  
  
  METHODS
  Receipt of lipid lowering therapy obtained from the VA pharmacy benefits management system was the main outcome.
  
  
  RESULTS
  The prevalence of lipid lowering therapy among HIV-infected and HIV-uninfected veterans was 15.4% vs. 37.9%, respectively, p < 0.01. Among veterans who met NCEP/ATP III criteria for lipid lowering therapy, HIV-infected veterans had a significantly lower prevalence for the receipt of lipid lowering therapy (adjusted odds ratio (OR) = 0.43, 95% confidence interval (C.I.) 0.28-0.67) as compared with HIV-uninfected veterans. Among HIV-infected veterans, log HIV viral load (adjusted OR = 0.57, 95% CI, 0.41-0.81) and HIV-HCV co-infection (adjusted OR = 0.31, 95% CI = 0.13-0.75) were negatively associated with receipt of lipid lowering therapy. Exposure to HAART was not associated with receipt of lipid lowering therapy.
  
  
  CONCLUSIONS
  Among those who met NCEP/ATP III criteria for lipid lowering therapy, HIV-infected veterans, particularly those with high HIV viral loads and HCV co-infection, were significantly less likely to receive lipid lowering therapy. This may be a modifiable mediator of cardiovascular disease among HIV-infected individuals.
authors.affiliation: University of Pittsburgh, Center for Research on Health Care, Pittsburgh, PA, USA. freibergms@upmc.edu
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Freiberg
authors.forename: David A
authors.initials: DA
authors.lastname: Leaf
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Goulet
authors.forename: Matthew B
authors.initials: MB
authors.lastname: Goetz
authors.forename: Krisann K
authors.initials: KK
authors.lastname: Oursler
authors.forename: Cynthia L
authors.initials: CL
authors.lastname: Gibert
authors.forename: Maria C
authors.initials: MC
authors.lastname: Rodriguez-Barradas
authors.forename: Adeel A
authors.initials: AA
authors.lastname: Butt
authors.forename: Amy C
authors.initials: AC
authors.lastname: Justice
mesh_terms: D000328:Adult; D000368:Aged; D003327:Coronary Disease / Q000150:complications / Q000517:prevention & control; D003430:Cross-Sectional Studies; D015658:HIV Infections / Q000150:complications*; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications* / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010818:Practice Patterns, Physicians'; D011446:Prospective Studies; D014728:Veterans; D019562:Viral Load
chemical_list: D000960:Hypolipidemic Agents